Suki AI vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Redwood City ambient voice AI for physicians converting patient conversations into EHR-coded SOAP notes and diagnoses; integrates with major EHR systems to reduce documentation time.
About
Suki AI is a Redwood City-based clinical AI company that provides physicians with an ambient voice assistant that listens to patient-physician conversations during appointments and automatically generates structured clinical notes in the EHR, dramatically reducing the documentation burden that contributes to physician burnout. Suki's AI processes natural conversation audio to extract clinically relevant information, populate SOAP notes, and code diagnoses and procedures — turning a 15-minute documentation task into a 2-minute review and sign-off. The platform integrates with major EHR systems including Epic, Cerner, and Athena and is designed to fit naturally into clinical workflows without requiring physicians to change how they see patients. Suki serves health systems, physician groups, and telehealth companies looking to improve clinician efficiency and satisfaction. Founded in 2017 by former Google and Flipkart executives, Suki raised over $165M from investors including Venrock, First Round Capital, and Flare Capital Partners. It competes with Nuance DAX, Abridge, and DeepScribe in the ambient AI documentation market.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.